Equitar en es it fr

Equitar Brand names, Equitar Analogs

Equitar Brand Names Mixture

  • No information avaliable

Equitar Chemical_Formula


Equitar RX_link

No information avaliable

Equitar fda sheet

Equitar msds (material safety sheet)

Equitar Synthesis Reference

No information avaliable

Equitar Molecular Weight

309.469 g/mol

Equitar Melting Point

< 25 oC

Equitar H2O Solubility

Soluble as HCl salt

Equitar State


Equitar LogP


Equitar Dosage Forms

Tablets (oral, 1 mg)

Equitar Indication

Used for the symptomatic treatment of parkinsonism.

Equitar Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Equitar Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Equitar side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Equitar Patient Information

Equitar Organisms Affected

Humans and other mammals